Side-by-side · Research reference

ChonlutenvsHexarelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BPhase 1HUMAN-REVIEWED19/45 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

Hexarelin

Hexapeptide GHRP · Cardio-tropic

100–200 mcgPer doseSmith 1996

Phase 1Evidence levelGhigo 1997

~70 minHalf-lifeSemenistaya 2010

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Chonluten

Hexarelin

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

Ghrelin receptor (GHS-R1a) + cardiac CD36Smith 1996 Ghigo 1997

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

GHS-R1a → Gαq → Ca²⁺ → GH release. CD36 engagement → direct cardio-tropic actionGhigo 1997

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Strong GH pulse + IGF-1 elevation; cardio-protective effects in animal MI modelsGhigo 1997

Feedback intact?

—

Yes initially; tachyphylaxis with chronic useGhigo 1997

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Synthetic hexapeptide His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂Smith 1996

Antibody development

—

02Dosage Protocols

Parameter

Chonluten

Hexarelin

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

1–2× per day max (tachyphylaxis with chronic 3× daily)

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

—

Evidence basis

In vitro mechanistic

Phase 1 / Phase 2 trialsSmith 1996 Ghigo 1997

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

4–8 weeks on / 4–8 weeks off (tachyphylaxis mitigation)

Clinical validation

None (PubMed indexed)

—

Standard dose

—

100–200 mcg per injectionSmith 1996

Lower / starter dose

—

50 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep + fasted preferred

Half-life

—

~70 minSemenistaya 2010

04Side Effects & Safety

Parameter

Chonluten

Hexarelin

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Cortisol elevation

—

Modest at high dosesGhigo 1997

Prolactin elevation

—

Modest at high dosesGhigo 1997

Hunger

—

Strong appetite increase via ghrelin agonism

Tachyphylaxis

—

Receptor desensitisation with chronic dosingGhigo 1997

Cardiac effects

—

Direct cardio-tropic; potential benefit in MI but unstudied in humansGhigo 1997

IGF-1 elevation

—

Strong; monitor with chronic high-dose use

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

Hexarelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

Hexarelin

·Untreated diabetes
·Severe hyperprolactinemia

05Administration Protocol

Parameter

Chonluten

Hexarelin

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

SQ — abdomen or thigh. Rotate sites.

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

Pre-sleep + fasted preferred. Cycle on/off to avoid tachyphylaxis.

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Chonluten

— no documented stacks

Hexarelin

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

Hexarelin (GHRP) + CJC-1295-no-DAC (GHRH analogue) is the higher-amplitude variant of the standard GHRH+GHRP stack. Hexarelin produces a stronger pulse than ipamorelin but with cortisol + prolactin signal — choose this stack for maximum GH amplitude when side-effect tolerance is acceptable. Cycle aggressively.

Hexarelin: 100 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: Maximum GH pulse amplitude (with side-effect signal)

Smith 1996 Teichman 2006